McKesson (MCK) official guidance

In corporate, we anticipate expenses of $580 million-$640 million.

As a result, we estimate weighted average diluted shares outstanding to be in the range of 115.5 million-117.5 million.

We also anticipate the full year effective tax rate of 18%-19%, a slight increase from the prior guidance range driven by incremental tax expenses, result of higher operating profit growth.

We're pleased with the strength of our first quarter performance, which gives us the confidence to raise full-year adjusted earnings per diluted share guidance to $44.20-$45 from the prior range of $43.80-$44.60.

We anticipate free cash flow of approximately $4.5 billion-$4.9 billion.

We expect interest expense to be in the range of $380 million-$420 million, reflecting financing activities completed in support of the Medsurg separation.

We expect income attributable to non-controlling interest of $295 million-$325 million, which includes the minority ownership interest in Medsurg.

Moving now to Medsurg segments, we anticipate revenue growth of 1%-6% and operating profit growth of flat to 4%.

In North American Pharmaceutical, we anticipate revenue growth of 4%-8% and operating profit growth at the high end of the previous range of 5.5%-9.5%.

Turning to Oncology & Multispecialty, we continue to anticipate revenue growth of 14.5%-18.5% and operating profit growth of 13.5%-17.5%.

In Prescription Technology Solutions, we anticipate revenue to increase by 2.5%-6.5% and operating profit to increase 11%-15%.

For fiscal 2027, we anticipate revenue growth of 5%-9% and operating profit growth of 9%-13%.

Moving now to Medsurg segments, we anticipate revenue growth of 1%-6% and operating profit growth of flat to 4%.

In North American Pharmaceutical, we anticipate revenue growth of 4%-8% and operating profit growth at the high end of the previous range of 5.5%-9.5%.

Turning to Oncology & Multispecialty, we continue to anticipate revenue growth of 14.5%-18.5% and operating profit growth of 13.5%-17.5%.

In Prescription Technology Solutions, we anticipate revenue to increase by 2.5%-6.5% and operating profit to increase 11%-15%.

For fiscal 2027, we anticipate revenue growth of 5%-9% and operating profit growth of 9%-13%.

We expect repurchasing approximately $5 billion worth of shares during fiscal 2027, of which $2.5 billion was completed in the first quarter.

Wrapping up fiscal 2027 guidance, we anticipate revenue growth of 5%-9% and adjusted operating profit growth of 8%-12%.

We anticipate corporate expenses to be in the range of $620 million-$650 million, which includes the year-to-date impact, $15 million of pre-tax gains from equity investments within the McKesson Ventures portfolio.